MARKET WIREStockInvest.us • 19h ago
Candel Therapeutics Stock Price Forecast. Should You Buy CADL?StockInvest.us report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
Why CADL Stock dropped -3.70% Today — RQD Quant Desk Flash
$8.33 -3.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $8.26
Candel Therapeutics Inc. (CADL) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $637.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CADL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CADL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Candel Therapeutics Inc. (NASDAQ: CADL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $8.33 (-3.70% 1D, market cap $637.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CADL ranks #674 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CADL compare to AURA and IAM in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CADL carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AURA (Aura Biosciences Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and IAM (Iambic Therapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $636.6M). Among the 5-stock peer group, CADL leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CADL?
▼
Per CADL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001841387), Candel Therapeutics Inc. generated $135.1M in revenue (+44.6% YoY), -$38.2M in net income, and -$38.9M in free cash flow against $125.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $8.26 (-0.86%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CADL)Realized 20D OHLCV Swing Band: ±11.8%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY CADL SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (33% of score)
FRED Regime × Technicals: 41% of 52W Range • RSI-14 at 39.3 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$9.27-6.8% Next Q
41
Q2 (-2Q)Grade E$8.64-4.5% Next Q
38
Q3 (-1Q)Grade E$8.25+1% Next Q
36
CurrentGrade E$8.33-8.9% Hist 90D α
33
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CADL Turnaround Squeeze
While CADL currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.50) and Max Pain ($8.75) forces dealer call-delta covering toward $14.70.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CADL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CADL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CADL Stock dropped -3.70% Today — RQD Quant Desk Flash
Candel Therapeutics Inc. (CADL) dropped -3.70% to $8.33, trading at 41% of its 52-week range ($4.35 – $14). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 41% of its 52-week range ($4.35 – $14) with RSI-14 at 39.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.8% around $8.33 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CADL Headlines & Catalysts
MARKET WIRETradingView • 22h ago
Candel Therapeutics, Inc. Estimates – NASDAQ:CADLTradingView report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Candel Therapeutics, Inc. (CADL) Options Chain - Yahoo FinanceYahoo! Finance Canada report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Analysts Expect Breakeven For Candel Therapeutics, Inc. (NASDAQ:CADL) Before LongSimply Wall St report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Candel Therapeutics (CADL) Short Interest & Short Float | Updated Oct 2026MarketBeat report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 1d ago
13 Biotech Stocks to Watch: Candel (NASDAQ:CADL), Verastem (NASDAQ:VSTM), Surrozen (NASDAQ:SRZN) and Ten Other Nasdaq Biotech Stockskalkine.ca report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
A legal executive with 20 years' experience will join Candel as it plans to seek approval for a prostate cancer treatment.Stock Titan report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Candel Therapeutics to Present at November Investor ConferencesYahoo Finance report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate CancerNEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d
MARKET WIREBenzinga • 5d ago
Candel Therapeutics' Abstract From Its Phase 2 PrTK05 Clinical Study Of Aglatimagene Besadenovec Accepted For Presentation At Society For Immunotherapy Of Cancer’s 41st Annual MeetingCandel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CADL)
- ✓Walkthrough of CADL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CADL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +10.62%📐 HORIZONTAL RANGE
2026-11-03O $8.65H $8.65L $8.33C $8.33VOL 779.9K
RES: $17.09SUP: $7.58SMA50: $10.50SMA200: $8.31
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CADL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CADL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CADL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CADL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CADL)
Health Care Rank #674 of 1016
⚔️ AURA vs CADL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CADL vs. AURA, IAM, FDMT, SLDB)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Candel Therapeutics Inc. (CADL) ranks #674 by composite RQD confidence (33/100, grade E) and #405 by equity capitalization ($637.4M). Within this direct 5-issuer industry benchmark cohort, CADL leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with CADL at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CADL
ACTIVE
Candel Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -3.70% | $637.4M | Benchmark Subject |
| AURA Aura Biosciences Inc. | E | 29/100 | — | — | -35.0% | -2.46% | $636.7M | /aura-vs-cadl → |
| IAM Iambic Therapeutics Inc. | D | 47/100 | — | — | — | -5.95% | $636.6M | /iam-vs-cadl → |
| FDMT 4D Molecular Therapeutics Inc. | D | 44/100 | — | — | -28.3% | -6.89% | $657.4M | /fdmt-vs-cadl → |
| SLDB Solid Biosciences Inc. | E | 26/100 | — | — | -35.0% | -2.97% | $664.8M | /sldb-vs-cadl → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001841387In its most recent audited fiscal period (FY2025, filed 2025-12-31), Candel Therapeutics Inc. (CADL) reported GAAP revenue of $135.1M (+44.6% vs. FY2024 revenue of $93.4M , and +25.7% cumulative change since FY2023) , GAAP net income of -$38.2M, operating cash flow of -$38.3M, and free cash flow of -$38.9M (-43.9% YoY). On the balance sheet, CADL closed FY2025 with $125.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $135.1M | -$38.2M | -$38.3M | -$38.9M | $125.2M | — |
| FY2024 (FY) | 2024-12-31 | $93.4M | -$55.2M | -$27.0M | -$27.0M | $106.9M | $1.7M |
| FY2023 (FY) | 2023-12-31 | $107.5M | -$37.9M | -$34.2M | -$34.2M | — | — |
3. CADL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CADL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Candel Therapeutics Inc. (NASDAQ: CADL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $8.33 (-3.70% 1D, market cap $637.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CADL ranks #674 in composite RQD confidence.
How does CADL compare to AURA and IAM in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CADL carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AURA (Aura Biosciences Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $636.7M) and IAM (Iambic Therapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $636.6M). Among the 5-stock peer group, CADL leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CADL?
Per CADL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001841387), Candel Therapeutics Inc. generated $135.1M in revenue (+44.6% YoY), -$38.2M in net income, and -$38.9M in free cash flow against $125.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CADL trading relative to its 50-day, 200-day, and 52-week technical levels?
CADL last traded at $8.33 (-3.70% on volume of 779,948 shares), positioning the stock -20.67% below its 50-day simple moving average ($10.50) and +0.24% above its 200-day simple moving average ($8.31). Across its 52-week range of $4.35 to $14.00, CADL sits at the 41.2% percentile with a 14-day RSI of 39.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.8% ($7.35 to $9.31).
ROARABLE RATING BRIEF • RQD 33/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
CADL — Candel Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:34:03Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CADL scores 34 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield -5.88%), the weakest reading in the rating; Whale 13F Flow at 6/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 11/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).
For a prospective investor, the pillar profile points to a company whose operating economics are negative. The balance sheet reads as middling rather than distressed, with cash reported at $119.7M in FY 2025, but the Piotroski F-Score of 2/9 signals weak fundamental quality. Insider and institutional signals are muted to weak. Any investment case here rests on future events not captured in the sources, which is the core reason the rating assigns a sell verdict.
Business
Candel Therapeutics Inc. (NASDAQ: CADL) is classified in the Health Care sector and the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile describes it as a NASDAQ-listed issuer with a market capitalization of $0.7B. How the company intends to generate revenue is —
Recent Catalysts & News Wire Analysis
Per the recent news wire, six items reference CADL, all published within roughly 15 hours before the data timestamp, and each carries a YELLOW light and "MARKET WIRE" impact label. The headlines reference a stock price forecast from StockInvest.us, a TradingView estimates page, Yahoo Finance options chain coverage, a Simply Wall St note on analysts expecting breakeven, a MarketBeat short interest update dated October 2026, and a kalkine.ca list of biotech stocks to watch. These items are general market commentary; none describes a specific clinical, regulatory, or financing event in the provided text. Risk watch items drawn from the data are the short-interest reference and the negative cash flow. Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, there are no upstream or downstream links and no proprietary signals in the source data. Sector correlation beyond the Health Care classification and the beta of 1.0 is — Second-order bottlenecks are —
Open Questions
1.
- What is the company's cash runway relative to the FY 2025 FCF of $-38.9M, and will new financing be needed?
- Why is the FY 2023 cash and debt position marked N/A, and what are the full balance sheet figures?
- What drove the year-over-year change in net loss between FY 2024 and FY 2025?
- What are the TTM earnings, forward estimates, and any analyst coverage, none of which appear in the source data?
CADL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Candel Therapeutics Inc. (CADL) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE StockInvest.us • 19h ago
Candel Therapeutics Stock Price Forecast. Should You Buy CADL? StockInvest.us report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 22h ago
Candel Therapeutics, Inc. Estimates – NASDAQ:CADL TradingView report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Candel Therapeutics, Inc. (CADL) Options Chain - Yahoo Finance Yahoo! Finance Canada report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Analysts Expect Breakeven For Candel Therapeutics, Inc. (NASDAQ:CADL) Before Long Simply Wall St report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Candel Therapeutics (CADL) Short Interest & Short Float | Updated Oct 2026 MarketBeat report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 1d ago
13 Biotech Stocks to Watch: Candel (NASDAQ:CADL), Verastem (NASDAQ:VSTM), Surrozen (NASDAQ:SRZN) and Ten Other Nasdaq Biotech Stocks kalkine.ca report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
A legal executive with 20 years' experience will join Candel as it plans to seek approval for a prostate cancer treatment. Stock Titan report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Candel Therapeutics to Present at November Investor Conferences Yahoo Finance report covering Candel Therapeutics Inc. (CADL) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CADL Bull vs. Bear Conversation Board — What's Your Call at $8.33?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CADL 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $10.08 (+21.0%)
📌 Pinned Debate Reported cash of $119.7M at FY 2025 provides a balance sheet cushion against the $-38.9M free cash outflow.
Reported cash of $119.7M at FY 2025 provides a balance sheet cushion against the $-38.9M free cash outflow.. When you look under the hood at CADL, Fundamental Cash Engine is 4/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $14.00. My 12M target is $10.08.
RetailWhale_TX 🐂 BULL
Both sides have a point here — CADL's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
SH ShortSeller_Dan Forensic Short Bias 🐻 BEARISH
🎯 Target: $7.16 (-14.0%)
Spot @ $8.33 ROIC of -35% and negative net income in every reported period show the operating engine is not yet generating returns.
Fading this rally in CADL at $8.33. ROIC of -35% and negative net income in every reported period show the operating engine is not yet generating returns.. With a beta of 1.0 and the stock sitting at $8.33 (52-wk range $4.35–$14.00), the easy multiple expansion is already priced in.